Red Flags Detected
- Delisting (new) — Company faces potential delisting from Nasdaq for failing to maintain minimum $1.00 bid price requirement.
GT Biopharma gets 180-day extension to regain Nasdaq compliance, faces delisting risk
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
4 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade GTBP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
View original filing on SEC.gov
Generated by AI · May 25, 2026 12:11 PM